The Three Greatest Moments In Tumor Treating Fields Mesothelioma History

Tumor Treating Fields Mesothelioma

Tumor treating mesothelioma from fields is a new type of therapy that uses alternating electric fields to stop the growth of cancer. It is used in conjunction with chemotherapy to treat mesothelioma of the pleural region.

The FDA approved TTFields concomitant with pemetrexed and Cisplatin in 2019, following the success of the STELLAR trial. Patients can ask their specialist for this treatment.

Disrupting Cell Division

TTFields uses different electrical fields that disrupt cancer cell protein and block the cells from dividing. This can prevent mesothelioma cells from expanding or spreading to other organs within the body. The TTFields help to trigger the release of proteins that kill cancerous cells and assist the immune system in fighting mesothelioma tumours.

During treatment the patient wears a small device with insulated pads that adhere to the skin. The device delivers a low-intensity electrical current and the patient is able to decide how much treatment they receive. The duration of a mesothelioma treatment session is typically 30 minutes. Patients can undergo TTFields treatments several times per day.

A TTFields study that was published in 2021 showed that the electrical field intensity of 100-300 Kilohertz could stop cell division in cancer cells and cause them to die. The study included a variety of cancerous cells and found that the electrical fields killed them all, regardless of their cellular shape.

The author of the study suggested combining TTFields and chemotherapy for mesothelioma. FDA approved Novocure's TTFields NovoTTF 100L in the year 2019 for the treatment of non-resectable mesothelioma pleural. It is now available through mesothelioma specialists from accredited medical centers in the U.S. including the West Cancer Center, Memphis. The NovoTTF-100L medical device, now known as Optune Lua, has been used to treat mesothelioma in combination with chemotherapy based on platinum. Mesothelioma patients have reported longer survival time when the TTFields therapy is combined with chemotherapy.

Another study, which was published in "Lung Cancer", reported that TTFields therapy is effective with chemotherapy. Researchers found that the combination of chemotherapy and TTFields significantly reduced the number mesothelioma tumors that are malignant in animal models. The study also revealed that combination treatments can increase the production proteins that kill mesothelioma cancer cells and decrease the amount of cancerous DNA found in your body.

The TTFields procedure is a relatively recent treatment and many mesothelioma specialists do not offer it for patients suffering from pleural mesothelioma. However, patients might be able to access this treatment option through clinical trials or mesothelioma centers that are certified by Novocure.





Stalling Tumor Growth

When mesothelial cancer cells multiply and exceed their normal lifespan they develop mutated cells and may cause an overabundance of cells that increases and expands throughout the body. Tumor treatment fields prevent mesothelial cell duplication which prevents mesothelioma from spreading and growing.

The TTFields device is worn on the chest like the vest, and creates a series of electrical fields that destroy proteins that kill cancer cells and slow down tumor growth. The device is equipped with insulated pads that adhere to the skin. Patients or health care professionals can apply the pads at home.

Doctors suggest mixing TTFields with chemotherapy to achieve the most effective results. The combination increases production of proteins that destroy cancer cells and reduces cancer cells' ability to repair DNA damage from chemotherapy drugs. This allows chemotherapy drugs to work even harder, and improves the survival rate in mesothelioma sufferers.

In the STELLAR trial, which was conducted in 2017 TTFields therapy combined with chemotherapy significantly increased survival for mesothelioma patients. In the year 2019, the FDA approved the NovoTTF 100L System, now available under Optune Lua for use with pemetrexed, cisplatin, or carboplatin, as a primary treatment of malignant pleural melanoma that is not resectable.

Researchers have discovered that TTFields therapy works against mesothelioma because it interrupts cell division. The TTFields therapy causes cancer cells to split apart in a mitosis process. The cellular debris then gets trapped in the surrounding tissues and blocks the growth of new tissue. Mitosis also stops mesothelioma cancer cells from repair damaged DNA and makes cells more susceptible to radiation treatments.

The TTFields treatment may also reduce blood flow to the tumor by inhibiting vascular endothelial cellular growth factor, or VEGF, and increasing hypoxia-inducible factor-1 beta, or HIF-1a, which is associated with cancer cell angiogenesis.

If you are diagnosed with mesothelioma or other cancers, talk with your doctor about whether TTFields is a good option for you. Many mesothelioma specialists have partnered with Novocure on clinical trials to determine the efficacy of this new treatment. To learn more about how mesothelioma-TTFields might aid your treatment get in touch with a Novocure certified specialist at one of more than 1,300 U.S. treatment centers.

Killing Tumor Cells

Tumor-treating fields (TTFields), which send electrical waves throughout the body. They disrupt cell division and kill cancer cells. TTFields are low-intensity and intermediate frequency electrical fields that alternatingly are targeted at cancerous cells, without harming healthy ones. These electric fields also reduce DNA repair and enhance cell defenses, making it harder for cancerous cells to survive. TTF is non-invasive and causes only mild negative effects.

Scientists believe TTFields function by disrupting mitosis, a process by which the cell divides into two identical cells. Normal cells have control mechanisms to limit the rate of mitosis. However cancerous tumors of malignancy are able to break these restrictions and multiply at an accelerated rate. TTFields interferes with this process by blocking signals that control mitosis in mesothelioma cancer cells. In the STELLAR study TTFields when combined with chemotherapy significantly improved survival rates in mesothelioma patients. Mesothelioma patients who received TTFields along with maintenance cycles of chemotherapy lived six months longer on average than those who only received chemotherapy.

In a separate study, it was found that TTFields can boost the effectiveness of certain chemotherapy drugs known as platinum-based treatments. These platinum-based therapies destroy mesothelioma by targeting the mitochondria. This is where cancerous cell energy originates. When TTFields is combined with chemotherapies, the combination could result in higher levels DNA damage and faster death of cancer cells.

TTFields could also enhance the effects of radiation therapy in some cases. Scientists have observed that mixing TTFields with radiation therapy can result in an "synergistic effect." This means that the combination of treatments increases the sensitivity of mesothelioma tumor cells to radiation.

Currently, TTFields are available at certain mesothelioma centres. A mesothelioma doctor will determine if you're suitable for this treatment. If you do qualify mesothelioma lawyers can assist you in gaining access to treatment that may include TTFields alongside chemotherapy. If you are an veteran, a mesothelioma lawyer can help you get treatment that is covered by your VA health benefits.

Side Effects

The TT fields therapy disrupts cancer cells by creating an electrical field that hinders the cell's ability to divide. This can slow down the growth of tumors and stop the spread of cancer to other areas of the body. The TT fields device is noninvasive, which means it does not damage the tissues around it or cause discomfort. This is different from traditional chemotherapy, which requires injections into the vein or radiation, both of which can have serious side effects.

In the study in which patients received a combination of TT fields and temozolomide saw survival improvements comparable to those seen in patients treated with chemo on their own. Doctors attributing the improved survival to TT fields their ability to enhance the effectiveness of chemo and lessen the risk of side effects.

Mesothelioma cells can mutate into cancerous cells and replicate in uncontrolled ways to create an aggressive tumor that takes over the organs of your body. Mesothelioma treatments like TT fields stops mesothelioma from reproducing and limiting the body's normal functions by interrupting the division of cells.

In a mesothelioma study, mesothelioma patients who received TT fields along with chemotherapy had an average survival rate of 18.2 months. Patients who received TT fields but not chemotherapy had a rate of 12.1.

Tumor-treating fields are applied to the pleura, or the thin lining that covers your lungs, on your chest or abdominal wall. The device is small enough to wear for up to 18 hours each day, even during sleep. Patients are able to live their lives and work during treatment.

TT fields can be combined with traditional chemotherapy, immunotherapy or other mesothelioma treatment options. Mesothelioma patient who are interested in TT should discuss the option with their doctor. They can explain the eligibility requirements and the benefits that are expected for each patient's case.